Breaking News

Three-dose vaccination elicits neutralising antibodies against omicron

Omicron, the SARS-CoV-2 B.1.1.529 variant of concern (VOC), was first detected in southern Africa in November, 2021, and its BA.1 sub-lineage is now dominant in the UK. Omicron BA.1 contains 32 coding changes in its spike protein (appendix p 2), and it is unclear to what extent its spread is driven by an intrinsic increase in transmissibility or escape from previous infection-induced and vaccine-induced immunity.
In the UK, the BNT162b2 (Pfizer–BioNTech) and AZD1222 (ChAdOx1 nCoV-19, Oxford–AstraZeneca) COVID-19 vaccines were administered as part of a primary two-dose course. A subsequent third dose of either BNT162b2 or mRNA1273 (Moderna) vaccine has been administered since September, 2021. To determine the ability of vaccine-induced antibodies to neutralise omicron, and to compare this to our previous measurements of VOC neutralisation by BNT162b2 and AZD1222,

  • Wall EC
  • Wu M
  • Harvey R
  • et al.
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.